Form 4: Neurocrine Biosciences Executive Eric Benevich Reports Stock Sale Under 10b5-1 Plan
SEC Form 4 Filing
Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the sale of 1,207 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On January 31, 2025, Benevich sold 1,207 shares of Neurocrine Biosciences common stock at a weighted average price of $152.94 per share.
- This transaction was executed under a Rule 10b5-1 trading plan adopted on September 12, 2022.
- Benevich also acquired 2,294 shares of common stock through the vesting of restricted stock units (RSUs).
- Following these transactions, Benevich directly owns 41,919 shares of Neurocrine Biosciences common stock.
- He also holds 2,294 restricted stock units.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of stock transactions by an insider. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company. The vesting of RSUs is a positive sign of continued compensation.
Positives
- The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
- The vesting of restricted stock units indicates continued equity compensation for the reporting person.
Future Outlook
The RSU will continue to vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.
Comparison to Industry Standards
- Executive stock sales are common across the biotechnology industry, often driven by personal financial planning or diversification strategies.
- Companies like Amgen, Biogen, and Gilead Sciences also see regular Form 4 filings from their executives.
- The use of 10b5-1 plans is a standard practice among publicly traded companies to ensure compliance with insider trading regulations.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates this concern.
- The vesting of RSUs has no immediate impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2022-09-12 | Date of adoption of Rule 10b5-1 trading plan |
| 2022-01-31 | Date the Restricted Stock Unit was granted to the Reporting Person |
| 2023-01-31 | Date 2,293 shares vested |
| 2024-01-31 | Date 2,294 shares vested |
| 2024-08-31 | Date 54 shares were purchased from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan |
| 2025-01-31 | Date of stock sale and vesting of 2,294 shares |
| 2026-01-31 | Date 2,294 shares will vest |
| 2025-02-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.